BRYAN, Texas--(BUSINESS WIRE)--
Nutrabolt, a globally recognized leader in sports nutrition whose brand
portfolio includes the award winning Cellucor® and Scivation® brands of
dietary supplements, is proud to announce that it has partnered with
Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a
leading formulator, manufacturer and marketer of customized nutritional
supplements, to extend its license to patented CarnoSyn® beta-alanine
through 2026.
On June 6, 2017, the U.S. Patent and Trademark Office issued a new
patent to NAI directed to a broad range of improved methods of
beta-alanine intake, targeting such benefits as delaying muscle fatigue,
increasing anaerobic capacity, increasing muscle strength and increasing
muscle endurance. This new intellectual property significantly extends
the patent coverage for CarnoSyn® beta-alanine. Nutrabolt, given its
market dominance in sports nutrition and vision for the future of
nutrition in sports and other fields, was a natural business partner for
NAI. Nutrabolt is proud to include the patented, trademarked, and
clinically studied CarnoSyn® beta-alanine in several of its products,
including its award winning C4® brand of pre-workout products. CarnoSyn®
beta-alanine is not only included in the category leading C4® Original
pre-workout product but is included in a variety of newly released C4®
branded products including C4 Ripped®, C4 Sport®, C4 Extreme EnergyTM,
C4 Ultimate® and its ready to drink formula C4 On The Go®.
As the only clinically studied form of beta-alanine, CarnoSyn®
beta-alanine has been shown to provide numerous performance enhancing
benefits including an increase in muscular endurance, making it the
perfect addition to a pre-workout product engineered to improve
performance. Nutrabolt is proud to display the CarnoSyn® logo on its C4®
and other product labels and to continue to conduct University based
clinical studies on the performance enhancing benefits of its formulas
containing CarnoSyn® beta-alanine. Nutrabolt is proud to partner with
NAI, who has a long history of investing significant monies funding
research and brand awareness related to beta-alanine around the world,
as well as vigorously protecting its intellectual property rights
against infringers, providing further value to its licensees.
Doss Cunningham, CEO of Nutrabolt said that "since its inception in
2002, our company has focused on bringing new technology and innovative
product solutions to the sports nutrition industry. We are also
constantly looking at using high quality, patented ingredients, backed
by strong science. NAI's CarnoSyn® beta-alanine is supported by dozens
of scientific studies and a global intellectual property estate. We
value and respect NAI's investment in research and IP surrounding
CarnoSyn®. The notice of its recent patent allowance, extending its
coverage of uses related to beta-alanine, led to very productive
discussions with NAI about the future of beta-alanine, not just in
sports nutrition, but other fields that are growing rapidly. Nutrabolt
has always been a company that puts its customers first and constantly
searches for innovative product offerings and improved methods of use.
NAI's IP portfolio surrounding CarnoSyn® beta-alanine demonstrates,
through science, methods of use that benefit consumers. We look forward
to working with NAI in several areas and to promoting its patented
CarnoSyn® beta-alanine as an ingredient in Nutrabolt products."
Mark A. LeDoux, NAI's CEO and Chairman of the Board, said that "NAI is
very excited by the execution of this agreement with Nutrabolt extending
its worldwide license to our CarnoSyn® patent and trademark rights. The
recent addition of NAI's new patent, directed to a broad range of
improved methods of beta-alanine intake, is the future of beta-alanine
in sports nutrition." LeDoux went on to say that "during our meetings
with Nutrabolt executives and its research team, we explored other
fields of use for CarnoSyn® that NAI holds patent rights to, uses beyond
sports nutrition and for which it continues to explore through funded
research around the world. The opportunity to work with a market leader
like Nutrabolt related to CarnoSyn® was an easy decision for us."
About Nutrabolt
Nutrabolt is a global nutritional life sciences company established in
2002 that specializes in consumer product solutions in sports nutrition
and functional foods. The Company's marquee brand, Cellucor, includes
the brand's most notable product line C4, which has become the
uncontested industry leader in pre-workout supplementation. Nutrabolt
also owns Royal Sport and through a recent acquisition, Scivation Inc.,
best known for its XTEND branded product line. Nutrabolt launched its
way into functional foods in 2016 through its FitJoy branded line of
healthy on-the-go protein based snacks. Nutrabolt's brands are
distributed to some of the world's largest specialty, big box and online
retailers including GNC, Vitamin Shoppe, Amazon.com, Bodybuilding.com,
Walmart, Costco, and Target. Nutrabolt's brands are distributed in more
than 40 countries through its network of global distributors.www.nutrabolt.com
NAI, headquartered in Carlsbad, California, is a leading formulator,
manufacturer and marketer of nutritional supplements and provides
strategic partnering services to its customers. NAI's comprehensive
partnership approach offers a wide range of innovative nutritional
products and services to NAI's clients including scientific research,
clinical studies, proprietary ingredients, customer-specific nutritional
product formulation, product testing and evaluation, marketing
management and support, packaging and delivery system design, regulatory
review and international product registration assistance. For more
information about NAI, please see its website at http://www.nai-online.com
or http://www.carnosyn.com.
This press release contains forward-looking statements within the
meaning of applicable securities laws that are not historical facts and
information. These statements represent our intentions, expectations and
beliefs concerning future events, including, among other things, our
expectations and beliefs with respect to our future financial and
operating results, the outcome of pending litigation, the continued
validity of our patents, and our ability to successfully develop,
license and enforce our intellectual property rights. We wish to caution
readers these statements involve risks and uncertainties that could
cause actual results and outcomes for future periods to differ
materially from any forward-looking statement or views expressed herein.
NAI's financial performance and the forward-looking statements contained
herein are further qualified by other risks including those set forth
from time to time in the documents filed by us with the Securities and
Exchange Commission, including our most recent Annual Report on Form
10-K and Quarterly Report on Form 10-Q.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170626005368/en/
